Recruitment

Recruitment Status
Completed

Inclusion Criteria

Provision of signed informed consent
Age 18 and more
Index event of non-ST or ST segment elevation ACS
Provision of signed informed consent
Age 18 and more
Index event of non-ST or ST segment elevation ACS

Exclusion Criteria

Subjects with severe liver disease
High risk due to malignant hypertension
Positive pregnancy test or is known to be pregnant
...
Subjects with severe liver disease
High risk due to malignant hypertension
Positive pregnancy test or is known to be pregnant
Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers
Any life-threatening condition with life expectancy less than 6months
Thrombocytopenia or leukopenia
Increased bleeding risk
Subjects requiring dialysis
History of cerebral hemorrhage, gastrointestinal bleeding within 6months, major surgical procedure within 30days
Any other reason the investigator deems the subject to be unsuitable for the study e.g., Active malignant tumor
The conditions associated with increased risk of bradycardiac events
Mental condition (dementia, alcohol or drug abuse) which may be affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study
Hypersensitivity to aspirin or ticagrelor
Oral anticoagulation therapy that cannot be stopped
Treated with thrombolysis within 24hrs

Summary

Conditions
  • Acute Coronary Syndrome
  • Angina Pectoris
  • Cardiovascular Diseases
  • Heart Diseases
  • Myocardial Ischemia
Type
Interventional
Phase
Phase 4
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

Provision of signed informed consent
Age 18 and more
Index event of non-ST or ST segment elevation ACS
Provision of signed informed consent
Age 18 and more
Index event of non-ST or ST segment elevation ACS

Exclusion Criteria

Subjects with severe liver disease
High risk due to malignant hypertension
Positive pregnancy test or is known to be pregnant
...
Subjects with severe liver disease
High risk due to malignant hypertension
Positive pregnancy test or is known to be pregnant
Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers
Any life-threatening condition with life expectancy less than 6months
Thrombocytopenia or leukopenia
Increased bleeding risk
Subjects requiring dialysis
History of cerebral hemorrhage, gastrointestinal bleeding within 6months, major surgical procedure within 30days
Any other reason the investigator deems the subject to be unsuitable for the study e.g., Active malignant tumor
The conditions associated with increased risk of bradycardiac events
Mental condition (dementia, alcohol or drug abuse) which may be affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study
Hypersensitivity to aspirin or ticagrelor
Oral anticoagulation therapy that cannot be stopped
Treated with thrombolysis within 24hrs

Tracking Information

NCT #
NCT02094963
Collaborators
CardioVascular Research Foundation, Korea
Investigators
Not Provided